



2 October 2020

OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")

Preliminary report published by Ulster University

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the publication of the preliminary report of an independent evaluation of AbC-19™ by Ulster University.

The independent report compares three commercially available immunoassays to evaluate performance metrics for the AbC-19™ lateral flow test, which is developed by the UK-RTC. The report notes the lack of a well-accepted gold standard assay against which to measure any newly developed immunoassay designed to detect antibodies to SARS-CoV-2.

To overcome these challenges, a 'pseudo gold standard' system was established against which to analyse the sensitivity and specificity of each of the three commercially available immunoassays using a well characterised serology sample set to evaluate performance metrics for the AbC-19™ test. Using the 'pseudo gold standard' system the report concludes that the UK-RTC AbC-19 lateral flow immunoassay shows a sensitivity of 97.70% (95.72%-99.34%) and specificity of 100% (100.00-100.00%).

A link to the preliminary report can be found here:

<https://www.medrxiv.org/content/10.1101/2020.09.29.20201509v1>

Contacts:

Omega Diagnostics Group PLC

Bill Rhodes, Interim Non-Executive Chairman
Colin King, Chief Executive
Kieron Harbinson, Group Finance Director

Tel: 01259 763 030
www.omegadiagnostics.com

finnCap Ltd

Geoff Nash/Edward Whiley (Corporate Finance)
Alice Lane (ECM)

Tel: 020 7220 0500

Walbrook PR Limited

Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780 or omega@walbrookpr.com
Mob: 07980 541 893
Mob: 07584 391 303